abstracts

P055 Sociodemographic Differences in Fecal Enteropathogen Testing Patterns in Adults Hospitalized for Inflammatory Bowel Disease Flares

BACKGROUND: Adults with inflammatory bowel disease (IBD) have increased risks for gastrointestinal infections. Single-center studies in Michigan and New York r...

12/15/2021

P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic

BACKGROUND: Inflammatory Bowel Disease (IBD) is an inflammatory and chronic disease, as well as non-alcoholic fatty liver disease (NAFLD). Current literature has shown that IB...

12/15/2021

P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series

BACKGROUND: Tofacitinib is a molecule that inhibits Janus kinases, enzymes involved ulcerative colitis (UC) pathogenesis.

12/15/2021

P046 Tofacitinib Induced Resolution of Severe Colitis and Reactive Atypia in an Adolescent Patient With IBD

CASE: Tofacitinib is an anti-JAK/STAT small molecule approved for treatment of adults (but not children and adolescents) with moderate to severe ulcerative colitis. Data is li...

12/15/2021

P057 How Distance Between Residence and Treatment Center Impact the Outcome of Patients With Inflammatory Bowel Disease at CMN 20

BACKGROUND: Inflammatory bowel disease (IBD) affects an estimated 1.6 million people in the United States with at least 70,000 new cases per year. In the last 15 years an incr...

12/15/2021

P047 The Crohn’s Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials

BACKGROUND: In preparation for upcoming clinical trials involving patients with Crohn’s disease (CD), we examine the validity, reliability and usability of the Crohn’s Disease...

12/15/2021

P058 Impact of Inflammatory Bowel Disease Treatment and Risk of Covid-19 Infection after Full Immunization: A Nationwide Analysis

BACKGROUND: Acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a major challenge in patients with Inflammatory Bowel Disease (IBD) as immunosuppression used to t...

12/15/2021

P026 Inflammatory Bowel Disease (IBD) Related Outcomes in Patients Diagnosed With COVID-19

BACKGROUND: Patients with IBD report increased gastrointestinal symptoms, including diarrhea, abdominal pain, and nausea following COVID-19 diagnosis. While there has been a g...

12/15/2021

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator that selectively targets S1P 1 and S1P ...

12/15/2021

P027 Brain Fog in Patients With Inflammatory Bowel Disease, and Association With Use of Probiotics

BACKGROUND: Brain fog has been minimally studied in patients with inflammatory bowel disease (IBD). IBD patients frequently consume probiotics, whether sanctioned by a physici...

12/15/2021

abstracts

Follow Us on Twitter!

Specialties

Events

Year Round Education

HMP Global Products